Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,451-1,500 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__87_A6,9 | Lung | Primary cancer | 1,937 | Tumor/Malignant | 93.5% | 0.98 | 0.04 |
| NSCLC_38242124__IMC__87_A7,10 | Lung | Primary cancer | 2,605 | Tumor/Malignant | 87.0% | 0.97 | 0.07 |
| NSCLC_38242124__IMC__87_A7,12 | Lung | Primary cancer | 4,758 | Tumor/Malignant | 43.0% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__87_A7,13 | Lung | Primary cancer | 4,151 | Immune | 54.9% | 0.91 | 0.25 |
| NSCLC_38242124__IMC__87_A7,14 | Lung | Primary cancer | 3,253 | Tumor/Malignant | 65.5% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__87_A7,15 | Lung | Primary cancer | 2,902 | Tumor/Malignant | 46.1% | 0.95 | 0.16 |
| NSCLC_38242124__IMC__87_A7,16 | Lung | Primary cancer | 3,737 | Tumor/Malignant | 34.9% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__87_A7,17 | Lung | Primary cancer | 3,487 | Tumor/Malignant | 67.2% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_A7,2 | Lung | Primary cancer | 3,451 | Tumor/Malignant | 48.7% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__87_A7,3 | Lung | Primary cancer | 1,637 | Tumor/Malignant | 49.2% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__87_A7,4 | Lung | Primary cancer | 3,806 | Tumor/Malignant | 50.0% | 0.95 | 0.14 |
| NSCLC_38242124__IMC__87_A7,5 | Lung | Primary cancer | 2,094 | Tumor/Malignant | 34.2% | 0.93 | 0.34 |
| NSCLC_38242124__IMC__87_A7,6 | Lung | Primary cancer | 2,595 | Tumor/Malignant | 25.6% | 0.50 | 0.92 |
| NSCLC_38242124__IMC__87_A7,7 | Lung | Primary cancer | 3,480 | Tumor/Malignant | 31.0% | 0.88 | 0.36 |
| NSCLC_38242124__IMC__87_A7,8 | Lung | Primary cancer | 3,340 | Tumor/Malignant | 44.9% | 0.93 | 0.27 |
| NSCLC_38242124__IMC__87_A7,9 | Lung | Primary cancer | 2,881 | Tumor/Malignant | 39.6% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__87_A8,10 | Lung | Primary cancer | 5,468 | Tumor/Malignant | 96.8% | 1.00 | 0.00 |
| NSCLC_38242124__IMC__87_A8,11 | Lung | Primary cancer | 359 | Tumor/Malignant | 67.7% | 0.86 | 0.31 |
| NSCLC_38242124__IMC__87_A8,12 | Lung | Primary cancer | 4,213 | Tumor/Malignant | 71.2% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__87_A8,13 | Lung | Primary cancer | 5,888 | Immune | 40.8% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__87_A8,14 | Lung | Primary cancer | 2,819 | Tumor/Malignant | 34.9% | 0.98 | 0.15 |
| NSCLC_38242124__IMC__87_A8,15 | Lung | Primary cancer | 2,151 | Stromal | 40.3% | 0.89 | 0.34 |
| NSCLC_38242124__IMC__87_A8,16 | Lung | Primary cancer | 1,026 | Stromal | 34.0% | 0.48 | 0.79 |
| NSCLC_38242124__IMC__87_A8,17 | Lung | Primary cancer | 2,464 | Tumor/Malignant | 64.4% | 0.95 | 0.13 |
| NSCLC_38242124__IMC__87_A8,2 | Lung | Primary cancer | 3,633 | Tumor/Malignant | 30.6% | 0.97 | 0.18 |
| NSCLC_38242124__IMC__87_A8,3 | Lung | Primary cancer | 3,330 | Tumor/Malignant | 46.0% | 0.95 | 0.21 |
| NSCLC_38242124__IMC__87_A8,4 | Lung | Primary cancer | 3,352 | Tumor/Malignant | 33.4% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_A8,5 | Lung | Primary cancer | 3,203 | Tumor/Malignant | 56.5% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__87_A8,6 | Lung | Primary cancer | 3,005 | Tumor/Malignant | 39.1% | 1.00 | 0.05 |
| NSCLC_38242124__IMC__87_A8,7 | Lung | Primary cancer | 3,097 | Tumor/Malignant | 26.7% | 0.58 | 0.76 |
| NSCLC_38242124__IMC__87_A8,8 | Lung | Primary cancer | 2,518 | Stromal | 34.3% | 0.83 | 0.45 |
| NSCLC_38242124__IMC__87_A8,9 | Lung | Primary cancer | 2,976 | Tumor/Malignant | 76.6% | 0.95 | 0.16 |
| NSCLC_38242124__IMC__87_B1,1 | Lung | Primary cancer | 2,500 | Tumor/Malignant | 75.6% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__87_B1,10 | Lung | Primary cancer | 3,058 | Tumor/Malignant | 84.2% | 0.97 | 0.08 |
| NSCLC_38242124__IMC__87_B1,11 | Lung | Primary cancer | 2,689 | Tumor/Malignant | 65.4% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__87_B1,12 | Lung | Primary cancer | 2,296 | Tumor/Malignant | 66.2% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__87_B1,13 | Lung | Primary cancer | 3,976 | Tumor/Malignant | 56.3% | 0.92 | 0.24 |
| NSCLC_38242124__IMC__87_B1,14 | Lung | Primary cancer | 3,324 | Tumor/Malignant | 34.8% | 0.92 | 0.24 |
| NSCLC_38242124__IMC__87_B1,15 | Lung | Primary cancer | 1,374 | Stromal | 31.2% | 0.41 | 1.02 |
| NSCLC_38242124__IMC__87_B1,16 | Lung | Primary cancer | 1,351 | Tumor/Malignant | 80.2% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B1,17 | Lung | Primary cancer | 3,171 | Stromal | 29.2% | 0.51 | 0.83 |
| NSCLC_38242124__IMC__87_B1,2 | Lung | Primary cancer | 3,919 | Tumor/Malignant | 34.5% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__87_B1,3 | Lung | Primary cancer | 2,577 | Tumor/Malignant | 62.9% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__87_B1,4 | Lung | Primary cancer | 2,857 | Tumor/Malignant | 59.7% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__87_B1,5 | Lung | Primary cancer | 2,602 | Tumor/Malignant | 40.7% | 0.85 | 0.35 |
| NSCLC_38242124__IMC__87_B1,6 | Lung | Primary cancer | 513 | Tumor/Malignant | 55.6% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__87_B1,7 | Lung | Primary cancer | 3,546 | Tumor/Malignant | 67.2% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B1,8 | Lung | Primary cancer | 2,515 | Stromal | 30.7% | 0.54 | 0.86 |
| NSCLC_38242124__IMC__87_B1,9 | Lung | Primary cancer | 3,200 | Tumor/Malignant | 39.8% | 0.76 | 0.52 |
| NSCLC_38242124__IMC__87_B2,1 | Lung | Primary cancer | 2,416 | Tumor/Malignant | 76.6% | 0.99 | 0.07 |